---
title: "Definium Therapeutics climbs 7% to 52-week high on stock grant news"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292239021.md"
description: "Definium Therapeutics (DFTX) climbed 7% to 52-week high in regular trading on employee stock grant news."
datetime: "2026-07-09T20:21:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292239021.md)
  - [en](https://longbridge.com/en/news/292239021.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292239021.md)
---

# Definium Therapeutics climbs 7% to 52-week high on stock grant news

Definium Therapeutics(DFTX.US) 常规交易时段涨**6.91%**，股价触及 52 周高位，盘后现报**48.033 美元**。

消息面上，公司于 7 月 6 日向 8 名新入职非执行员工授予 169,740 份股票期权，该消息于 7 月 9 日被市场关注，推动股价创新高。

背景方面，公司 6 月下旬公布抑郁症药物 DT120 三期临床试验达到主要终点后，完成 7 亿美元融资用于研发及商业化准备。多家机构维持「买入」评级，目标价介于 50 至 70 美元。

### Related Stocks

- [DFTX.US](https://longbridge.com/en/quote/DFTX.US.md)

## Related News & Research

- [What Do Definium Therapeutics (DFTX) Phase 3 GAD Results Mean For DT120?](https://longbridge.com/en/news/295821556.md)
- [Definium Therapeutics (DFTX) Receives a Buy from Wells Fargo](https://longbridge.com/en/news/295787298.md)
- [Definium Therapeutics Says Unprecedented Efficacy From Anxiety Study 'Raises the Bar'](https://longbridge.com/en/news/295680444.md)
- [Definium says LSD-based pill reduces anxiety in late-stage study](https://longbridge.com/en/news/295653550.md)
- [Is Definium Therapeutics (DFTX) Expensive As New GAD Study Sharpens Its Late Stage Case?](https://longbridge.com/en/news/293649367.md)